Catalyst Funds Management Pty LTD Arcellx, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Arcellx, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 400 shares of ACLX stock, worth $38,772. This represents 0.01% of its overall portfolio holdings.
Number of Shares
400Holding current value
$38,772% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
201Shares Held
44.1MCall Options Held
2.1MPut Options Held
778K-
Paradigm Biocapital Advisors LP New York, NY4MShares$388 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$377 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$363 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$341 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$239 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $4.25B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...